These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 37511609)

  • 1. Neoadjuvant Immunotherapy: A Promising New Standard of Care.
    Boydell E; Sandoval JL; Michielin O; Obeid M; Addeo A; Friedlaender A
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.
    Agostinetto E; Losurdo A; Nader-Marta G; Santoro A; Punie K; Barroso R; Popovic L; Solinas C; Kok M; de Azambuja E; Lambertini M
    Expert Opin Investig Drugs; 2022 Jun; 31(6):567-591. PubMed ID: 35240902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation.
    Paver EC; Cooper WA; Colebatch AJ; Ferguson PM; Hill SK; Lum T; Shin JS; O'Toole S; Anderson L; Scolyer RA; Gupta R
    Pathology; 2021 Feb; 53(2):141-156. PubMed ID: 33388161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker.
    Signorelli D; Giannatempo P; Grazia G; Aiello MM; Bertolini F; Mirabile A; Buti S; Vasile E; Scotti V; Pisapia P; Cona MS; Rolfo C; Malapelle U;
    Biomed Res Int; 2019; 2019():9056417. PubMed ID: 31179334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant Chemoimmunotherapy in Patients with Resectable Non-small Cell Lung Cancer.
    Gutierrez-Sainz L; Cruz-Castellanos P; Higuera O; de Castro-Carpeño J
    Curr Treat Options Oncol; 2021 Aug; 22(10):91. PubMed ID: 34424417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?
    Chae YK; Pan A; Davis AA; Raparia K; Mohindra NA; Matsangou M; Giles FJ
    Clin Lung Cancer; 2016 Sep; 17(5):350-361. PubMed ID: 27137346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surgical Perspective on Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer.
    Lee JM; Tsuboi M; Brunelli A
    Ann Thorac Surg; 2022 Oct; 114(4):1505-1515. PubMed ID: 34339672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant Immunotherapy: Leveraging the Immune System to Treat Early-Stage Disease.
    Mittendorf EA; Burgers F; Haanen J; Cascone T
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-15. PubMed ID: 35714302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarkers of response to immunotherapy in early stage non-small cell lung cancer.
    Roulleaux Dugage M; Albarrán-Artahona V; Laguna JC; Chaput N; Vignot S; Besse B; Mezquita L; Auclin E
    Eur J Cancer; 2023 May; 184():179-196. PubMed ID: 36963241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time?
    Ahern E; Solomon BJ; Hui R; Pavlakis N; O'Byrne K; Hughes BGM
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34083418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy.
    Casarrubios M; Provencio M; Nadal E; Insa A; Del Rosario García-Campelo M; Lázaro-Quintela M; Dómine M; Majem M; Rodriguez-Abreu D; Martinez-Marti A; De Castro Carpeño J; Cobo M; López Vivanco G; Del Barco E; Bernabé R; Viñolas N; Barneto Aranda I; Massuti B; Sierra-Rodero B; Martinez-Toledo C; Fernández-Miranda I; Serna-Blanco R; Romero A; Calvo V; Cruz-Bermúdez A
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36171009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
    Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM
    Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 expression and Tumor mutation burden as Pathological response biomarkers of Neoadjuvant immunotherapy for Early-stage Non-small cell lung cancer: A systematic review and meta-analysis.
    Deng H; Zhao Y; Cai X; Chen H; Cheng B; Zhong R; Li F; Xiong S; Li J; Liu J; He J; Liang W
    Crit Rev Oncol Hematol; 2022 Feb; 170():103582. PubMed ID: 35031441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy Approaches for Breast Cancer Patients in 2023.
    Emens LA; Loi S
    Cold Spring Harb Perspect Med; 2023 Apr; 13(4):. PubMed ID: 37011999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy in Advanced Non-Small Cell Lung Cancer.
    Huang J; Reckamp KL
    Semin Respir Crit Care Med; 2020 Jun; 41(3):400-408. PubMed ID: 32450594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Immunotherapy in Breast Cancer.
    Jacob SL; Huppert LA; Rugo HS
    JCO Oncol Pract; 2023 Apr; 19(4):167-179. PubMed ID: 36608303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment.
    Krieger T; Pearson I; Bell J; Doherty J; Robbins P
    Diagn Pathol; 2020 Jan; 15(1):6. PubMed ID: 32000815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant immune checkpoint inhibitor therapy in resectable non-small cell lung cancer.
    Conroy MR; Dennehy C; Forde PM
    Lung Cancer; 2023 Sep; 183():107314. PubMed ID: 37541935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.